Mertens W C
Department of Medical Oncology, London Regional Cancer Centre, Ontario, Canada.
Semin Oncol. 1993 Jun;20(3 Suppl 2):49-55.
Systemically administered, beta-emitting radionuclides provide effective pain relief for many patients with symptomatic osseous metastases. Unfortunately, substantial numbers of patients achieve incomplete pain resolution, and some patients obtain no pain relief at all. In addition, there is little evidence that therapy with these radioisotopes results in improved overall survival, and relatively few patients exhibit evidence of significant antitumor activity. Strategies must be developed to enhance the effectiveness of this form of therapy. The possibilities of improved efficacy through the use of increased radionuclide dose, as well as radionuclide therapy in combination with colony-stimulating factors, radiosensitizing chemotherapy, bisphosphonates, and wide-field irradiation, will be explored, and the current literature as well as future plans will be reviewed. Many of these strategies hold promise for enhancing the palliative and anticancer effects of this form of therapy.
全身给药的发射β射线的放射性核素可为许多有症状的骨转移患者提供有效的疼痛缓解。不幸的是，相当数量的患者疼痛缓解不完全，有些患者根本没有疼痛缓解。此外，几乎没有证据表明用这些放射性同位素治疗能提高总体生存率，而且相对较少的患者表现出明显的抗肿瘤活性证据。必须制定策略来提高这种治疗方式的有效性。将探索通过增加放射性核素剂量以及放射性核素治疗与集落刺激因子、放射增敏化疗、双膦酸盐和广野照射联合使用来提高疗效的可能性，并将回顾当前的文献以及未来的计划。这些策略中的许多有望增强这种治疗方式的姑息和抗癌效果。
